Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
SOPHiA GENETICS (SOPH)
NASDAQ:SOPH
Holding SOPH?
Track your performance easily
Earnings Data
Report Date
Mar 11, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-0.21Last Year’s EPS
-0.37Same Quarter Last Year
Strong Buy
Based on 4 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 10, 2021
|% Change Since: -16.80%
|Next Earnings Date:Sep 09, 2021
Earnings Call Sentiment|Neutral
The earnings call highlighted strong clinical volume growth and effective cost management, including a significant improvement in cash burn and new product adoption. However, these positives were counterbalanced by a decline in biopharma revenue and overall revenue, as well as challenges in specific regions like Latin America and Spain.Company Guidance
During the SOPHiA GENETICS Q3 2024 earnings call, the company highlighted several key metrics and strategic updates. They reported a 16% year-over-year growth in analysis volume, reaching approximately 91,000 analyses, with a notable improvement in cash burn by 39% compared to the previous year. Adjusted gross margins stood at 73.1%, and adjusted operating loss improved by over 10% year-over-year. The company reaffirmed its 2024 revenue guidance in the range of $65 million to $67 million, representing a growth of 4% to 7%. They also highlighted the successful launch of MSK-ACCESS powered with SOPHiA DDM, which has been adopted by 18 customers across 10 countries, and the recent launch of MSK-IMPACT, anticipated to drive future growth. SOPHiA GENETICS also emphasized continued strong new business momentum and strategic leadership changes, including the promotion of Ross Muken to President and the appointment of George Cardoza as Chief Financial Officer.Clinical Volume Reacceleration
Performed approximately 91,000 analyses, representing year-over-year growth of 16% or 17% when excluding COVID-related volumes. New customer adoption and routine usage have increased.
Significant Cost Management
Achieved a 39% year-over-year improvement in cash burn and expanded gross margins to 73.1%.
New Product Launches and Adoption
Launch of MSK-ACCESS on SOPHiA DDM with adoption by 18 customers across 5 continents and 10 countries. Introduction of MSK-IMPACT powered with SOPHiA DDM.
Leadership Enhancements
Promotion of Ross Muken to Company President and appointment of George Cardoza as Chief Financial Officer.
---
SOPH Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
SOPH Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 05, 2024 | $3.75 | $3.75 | 0.00% |
| Aug 06, 2024 | $4.15 | $4.06 | -2.17% |
| May 07, 2024 | $5.05 | $4.97 | -1.58% |
| Mar 05, 2024 | $5.62 | $5.60 | -0.36% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does SOPHiA GENETICS (SOPH) report earnings?
SOPHiA GENETICS (SOPH) is schdueled to report earning on Mar 11, 2025, TBA Not Confirmed.
What is SOPHiA GENETICS (SOPH) earnings time?
SOPHiA GENETICS (SOPH) earnings time is at Mar 11, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is SOPH EPS forecast?
SOPH EPS forecast for the fiscal quarter 2024 (Q4) is -0.21.
---